Launch of i DTB Drug and Therapeutics Bulletin and Treatment Notes go online

2004 ◽  
Vol 42 (5) ◽  
pp. 33-33
Keyword(s):  
Therapeutics Bulletin

Cannabis

1967 ◽  
Vol 5 (25) ◽  
pp. 97-99
Keyword(s):  
Medical Practice ◽  
Illicit Drug ◽  
Cannabis Sativa ◽  
Psychosomatic Disorders ◽  
Synthetic Analogues ◽  
Therapeutics Bulletin ◽  
The Future

Preparations from Cannabis sativa, the hemp plant, were omitted from the B.P. in 1932, and from the B.P.C. in 1949. Today, they are scarcely used in medical practice, though manufacture of a tincture of cannabis is still licenced (and one or two practitioners are known to prescribe it from time to time for psychiatric or psychosomatic disorders1). Cannabis and preparations derived from it are controlled by the Dangerous Drugs Act, yet they are more widely and increasingly used in this country and in America than any other illicit drug. But this is not the only reason for discussing their effects in the Drug and Therapeutics Bulletin: the future use of some synthetic analogues and derivatives seems probable as analgesics, antidepressants and antihypertensives.2

Tests on disposable and re-usable needles part I - disposable needles

1964 ◽  
Vol 2 (8) ◽  
pp. 29-31
Keyword(s):  
Therapeutics Bulletin ◽  
Protective Packaging

The Drug and Therapeutics Bulletin carried out a series of tests on all brands of disposable needles available in October, 1963 (see Table I). Our tests were intended to assess and compare the different brands for sharpness, strength, non-leaking mount, and protective packaging, which are the most important requirements. In our next issue we shall report the results of similar tests on re-usable needles and shall compare the two types. Most tests were based on the British Standards (BS) 3522:1962 ‘Specification for Hypodermic Mounted Needles (Luer Fitting)’1. We tested at least 125 samples of each brand, which we bought anonymously. We tested Size No. 12 if we could get it, and, if not, the nearest size we could - No. 2 or No. 15.

Adverse drug reaction bulletin

1971 ◽  
Vol 9 (4) ◽  
pp. 16-16
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Regional Hospital ◽  
Therapeutics Bulletin ◽  
Extra Charge ◽  
Hospital Board

We are pleased to be able to announce a new service for our subscribers. With this issue, and every two months in future, they will receive the Adverse Drug Reaction Bulletin without extra charge. The ADRB has been published by the Newcastle Regional Hospital Board since 1966, but its circulation has until now been largely confined to the Newcastle Region. We believe that it deserves to be read much more widely and will be of particular value to readers of the Drug and Therapeutics Bulletin, to which it is complementary. The ADRB will retain its editorial independence, but we have arranged to print it and to distribute it for its publishers outside their region.

Drug therapy in anxiety, depression and other neurotic illnesses

1965 ◽  
Vol 3 (5) ◽  
pp. 17-18
Keyword(s):  
Mental Illness ◽  
Drug Therapy ◽  
Therapeutics Bulletin ◽  
Anxiety Depression

Several articles in the first two volumes of the Drug and Therapeutics Bulletin have been about drugs promoted for use in anxiety, depression and other illnesses of neurotic origin. There are no signs of any impending ‘breakthrough’ in the treatment of mental illness with drugs, nor is there any lessening of the tide of drugs promoted by manufacturers for this purpose: so the time seems opportune to comment on some principles of drug therapy in this field.

What is the evidence for the use of potassium permanganate for wound care?

2020 ◽  
Vol 58 (5) ◽  
pp. 71-74
Author(s):  
Varinder Rai
Keyword(s):  
Potassium Permanganate ◽  
Wound Care ◽  
Multiple Choice ◽  
Therapeutics Bulletin ◽  
Review Articles ◽  
Key Points

Topics for Drug and Therapeutics Bulletin (DTB) review articles are selected by DTB’s editorial board to provide concise overviews of medicines and other treatments to help patients get the best care. Articles include a summary of key points and a brief overview for patients. Articles may also have a series of multiple choice CME questions.

scholarly journals End of contract for Drug and Therapeutics Bulletin : Cost cutting, or worse?

BMJ ◽  
2006 ◽  
Vol 332 (7552) ◽  
pp. 1273.1
Author(s):  
Michael Schachter
Keyword(s):  
Therapeutics Bulletin ◽  
Cost Cutting

Drug and therapeutics bulletin index

1978 ◽  
Vol 16 (19) ◽  
pp. 76-76
Keyword(s):  
Therapeutics Bulletin

We are compiling a 5-year index for the issues of 1973–1977. This will be sent to subscribers as soon as it is published.

Announcement

1993 ◽  
Vol 31 (14) ◽  
pp. 56-56
Keyword(s):  
Pharmaceutical Industry ◽  
Health Economics ◽  
Price Regulation ◽  
Senior Managers ◽  
Pharmaceutical Price ◽  
Pharmaceutical Price Regulation Scheme ◽  
Therapeutics Bulletin ◽  
Regulation Scheme ◽  
Department Of Health

On Wednesday 15 SeptemberDrug & Therapeutics Bulletin will be holding a seminar on the “Implications of the new Pharmaceutical Price Regulation Scheme”. The seminar, which will take place at 2, Marylebone Road, London from 2.00 – 5.00pm, will be addressed by Melvyn Jeremiah, Under Secretary, Department of Health, Andrew Towse, Director, Office of Health Economics, Jane Richards, who chairs the Prescribing Sub-Committee, GMSC and Nick Bosanquet, Professor of Economics. The afternoon should interest health economists, senior managers in the pharmaceutical industry, government officers, NHS administrators and doctors concerned with costs issues. Those wishing to attend should send a cheque for £58.75 (includes VAT) payable to Consumers’ Association to: DTB seminar, 2 Marylebone Road, London NW1 4DF. Because of the very limited seating (50 places at most), applications plus payment should not be delayed. We have not applied for PGEA approval.

Therapeutic trials and society making the best use of resources

1986 ◽  
Vol 24 (10) ◽  
pp. 37-38
Keyword(s):  
Clinical Trials ◽  
Current Practice ◽  
Social Scientists ◽  
Therapeutics Bulletin ◽  
Therapeutic Trials ◽  
Use Of Resources

Clinical trials are essential to identify the best treatments for patients. Two years ago the Drug and Therapeutics Bulletin hosted a seminar on the implications of the current practice of therapeutic trials. Over 50 clinicians, medical scientists, statisticians and social scientists contributed. The discussions were chaired by Sir Douglas Black, Sir Richard Doll and Dr Peter Greenfield and now form the basis of a 24-page report published by the Consumers’ Association and available free on request*.

‘Which?’ supplement on contraceptives

1966 ◽  
Vol 4 (14) ◽  
pp. 56-56
Keyword(s):  
Oral Contraception ◽  
Test Results ◽  
Therapeutics Bulletin ◽  
Special Supplement

An extensively revised edition of this special supplement has just been published by Consumers’ Association. It brings test results and brand comparisons up to date, and gives more information about oral contraception and intra-uterine devices than the 1963 edition. The report is written for lay readers, but will also be particularly useful to doctors and pharmacists who may be asked for advice on contraception. The supplement costs 10/-, including postage; it is available to members of Consumers’ Association and to subscribers to the Drug and Therapeutics Bulletin.

Sign in / Sign up

Export Citation Format

Share Document